Quick Answer
International Stem Cell CORP reported R&D Expense of $684.0 thousand for fiscal year 2025.
International Stem Cell CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $684.0K | +4.1% |
| 2024 | $657.0K | +28.6% |
| 2023 | $511.0K | +3.9% |
| 2022 | $492.0K | -29.2% |
| 2021 | $695.0K | -29.7% |
| 2020 | $988.0K | -28.7% |
| 2019 | $1.39M | -42.2% |
| 2018 | $2.40M | -9.9% |
| 2017 | $2.66M | -6.9% |
| 2016 | $2.86M | +5.5% |
| 2015 | $2.71M | -49.7% |
| 2014 | $5.39M | +51.3% |
| 2013 | $3.56M | -1.1% |
| 2012 | $3.60M | -18.8% |
| 2011 | $4.43M | +31.4% |
| 2010 | $3.37M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $158.0K | -15.5% | -2.5% |
| June 30, 2025 | $162.0K | +95.2% | -13.4% |
| March 31, 2025 | $187.0K | +5.6% | +0.0% |
| September 30, 2024 | $187.0K | +20.6% | +125.3% |
| June 30, 2024 | $83.0K | +84.4% | -53.1% |
| March 31, 2024 | $177.0K | +22.1% | +14.2% |
| September 30, 2023 | $155.0K | +5.4% | +244.4% |
| June 30, 2023 | $45.0K | -45.8% | -69.0% |
- International Stem Cell CORP showed an increase of +4.1% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, International Stem Cell CORP’s r&d expense has declined by 79.7% (from $3.37 million to $684.0 thousand).
- The most recent figure is from International Stem Cell CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: